Valuation: Alvotech

Market Cap 1.78B 1.59B 1.47B 1.34B 2.52B 169B 2.56B 17.67B 6.93B 88.38B 6.7B 6.55B 282B P/E 2026 *
96.1x
P/E 2027 * 16.8x
Enterprise Value 2.86B 2.54B 2.36B 2.14B 4.05B 272B 4.11B 28.34B 11.11B 142B 10.74B 10.51B 452B EV / Sales 2026 *
4.34x
EV / Sales 2027 * 3.66x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-3.08%
1 week-1.90%
Current month-2.24%
1 month+11.18%
3 months+68.25%
6 months+56.63%
Current year+10.53%
1 week 4.95
Extreme 4.95
5.89
1 month 4.95
Extreme 4.95
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.74
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 57 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Executive Officer

117,271 0.0355%
1/4/26 Sell

Founder

318,000 0.0963%
1/4/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%-1.90%-35.20%-37.28% 1.78B
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.97%-1.10%+35.47%+73.41% 37.37B
Weighted average by Cap. -2.30%-1.18%+43.19%+87.98%

Financials

2026 *2027 *
Net sales 659M 586M 543M 494M 933M 62.57B 948M 6.53B 2.56B 32.65B 2.47B 2.42B 104B 776M 690M 639M 581M 1.1B 73.62B 1.11B 7.68B 3.01B 38.42B 2.91B 2.85B 122B
Net income 30.36M 26.99M 25.01M 22.76M 42.95M 2.88B 43.63M 301M 118M 1.5B 114M 112M 4.79B 109M 96.99M 89.89M 81.79M 154M 10.36B 157M 1.08B 424M 5.4B 409M 401M 17.23B
Net Debt 1.08B 957M 887M 807M 1.52B 102B 1.55B 10.66B 4.18B 53.33B 4.04B 3.96B 170B 1.06B 940M 871M 792M 1.5B 100B 1.52B 10.47B 4.1B 52.36B 3.97B 3.88B 167B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
16/10/26 USD 5.000 -5.84% 1,059,087
15/10/26 USD 5.310 +2.71% 1,156,272
14/10/26 USD 5.170 -3.90% 1,058,173
13/10/26 USD 5.380 -2.18% 1,214,031
12/10/26 USD 5.500 -4.84% 841,038
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.000USD
Average target price
6.800USD
Spread / Average Target
+36.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock